

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	14.6	89.3	(47.5-152.7)	Male	9	7.5	119.2	(54.4-226.3)
Female	2	6.0	nc	(nc-nc)	Female	8	6.3	127.2	(54.8-250.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	8	7.4	108.7	(46.8-214.3)
Female	70	61.8	113.3	(88.3-143.1)	Female	6	7.3	82.3	(30.0-179.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.7	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Colon / Rectum					Female	3	3.0	nc	(nc-nc)
Male	17	22.6	75.3	(43.8-120.5)	Ovary				
Female	27	24.5	110.3	(72.6-160.4)	Female	5	6.3	79.5	(25.6-185.5)
Esophagus					Pancreas				
Male	1	3.6	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	4	1.1	nc	(nc-nc)	Male	60	60.8	98.7	(75.3-127.1)
Female	2	1.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	2	3.8	nc	(nc-nc)
Male	9	6.0	150.1	(68.5-285.0)	Female	1	2.6	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Testis				
Larynx					Male	3	1.8	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)					

Female	1	0.7	nc	(nc-nc)
Leukemia				
Male	5	4.4	112.4	(36.2-262.2)
Female	6	4.0	148.3	(54.2-322.9)
Liver and Intrahepatic Bile Ducts				
Male	5	2.8	179.2	(57.7-418.1)
Female	0	1.2	nc	(nc-nc)
Lung and Bronchus				
Male	24	28.9	83.0	(53.2-123.6)
Female	32	27.1	118.0	(80.7-166.6)

Thyroid

Male	2	1.4	nc	(nc-nc)
Female	1	4.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	13	12.2	107.0	(56.9-183.0)
--------	----	------	-------	--------------

All Sites / Types

Male	178	197.5	90.1	(77.4-104.4)
Female	210	200.9	104.6	(90.9-119.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

155 Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	14	11.8	118.3	(64.6-198.5)
Female	11	4.4	250.3	(124.8-447.8)
Brain and Other Nervous System				
Male	3	2.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	51	46.6	109.4	(81.5-143.9)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	6.1	98.8	(36.1-215.0)
Female	7	5.0	140.4	(56.3-289.4)
Multiple Myeloma				
Male	2	1.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	6.0	116.6	(46.7-240.3)
Female	6	5.5	108.6	(39.7-236.5)
Oral Cavity & Pharynx				

Colon / Rectum	Female	1	2.2	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
	Male	25	18.3	136.9	(88.6-202.1)	Female	3	2.2	nc	(nc-nc)
	Female	15	18.1	82.9	(46.3-136.7)	Ovary				
Esophagus	Male	1	2.8	nc	(nc-nc)	Female	8	4.8	168.2	(72.4-331.4)
	Female	2	0.9	nc	(nc-nc)	Pancreas				
	Male	1	2.8	nc	(nc-nc)	Male	6	3.4	176.4	(64.4-383.9)
Hodgkin Lymphoma	Female	2	0.9	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)	Prostate				
	Female	1	0.9	nc	(nc-nc)	Male	49	46.9	104.6	(77.4-138.3)
Kidney & Renal Pelvis	Male	10	4.7	211.5	(101.2-388.9)	Stomach				
	Female	5	3.1	159.0	(51.3-371.1)	Male	1	3.1	nc	(nc-nc)
	Male	2	2.1	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
Larynx	Female	1	0.5	nc	(nc-nc)	Testis				
	Male	2	2.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)	Thyroid				
Leukemia	Male	1	3.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
	Female	1	3.2	nc	(nc-nc)	Female	5	3.9	129.7	(41.8-302.7)
	Male	1	3.7	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Liver and Intrahepatic Bile Ducts	Female	1	3.2	nc	(nc-nc)	Female	4	9.0	nc	(nc-nc)
	Male	1	2.2	nc	(nc-nc)	All Sites / Types				
	Female	0	0.9	nc	(nc-nc)	Male	180	157.3	114.4	(98.3-132.4)
Lung and Bronchus	Male	31	22.9	135.2	(91.8-191.9)	Female	157	151.3	103.7	(88.1-121.3)
	Female	16	20.0	80.1	(45.7-130.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

156
Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	8.9	78.9	(31.6-162.5)	Male	3	5.0	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	7	4.1	172.0	(68.9-354.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	1.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	33	38.2	86.3	(59.4-121.2)	Female	3	4.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.9	nc	(nc-nc)	Male	6	3.9	155.4	(56.8-338.3)
Colon / Rectum					Female	1	1.8	nc	(nc-nc)
Male	16	13.9	114.8	(65.6-186.5)	Ovary				
Female	7	13.6	51.3	(20.6-105.8)	Female	0	3.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	2.3	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.8	nc	(nc-nc)	Male	38	38.3	99.3	(70.3-136.3)
Female	1	0.7	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	2.4	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)					

Larynx	Female	3	2.5	nc	(nc-nc)	Testis	Female	0	1.5	nc	(nc-nc)
	Male	3	1.7	nc	(nc-nc)		Male	2	1.5	nc	(nc-nc)
Leukemia	Female	1	0.4	nc	(nc-nc)	Thyroid					
	Male	2	2.9	nc	(nc-nc)		Male	1	1.0	nc	(nc-nc)
	Female	0	2.5	nc	(nc-nc)		Female	3	3.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	2	1.8	nc	(nc-nc)						
	Female	0	0.7	nc	(nc-nc)		Female	7	7.4	95.1	(38.1-195.9)
Lung and Bronchus						All Sites / Types					
	Male	23	17.8	129.5	(82.0-194.3)		Male	125	125.0	100.0	(83.2-119.1)
	Female	17	15.4	110.4	(64.3-176.7)		Female	97	120.0	80.8	(65.6-98.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

157

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	6.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	0	0.2	nc	(nc-nc)
Female	24	24.7	97.0	(62.2-144.4)
Cervix Uteri				
Female	0	1.2	nc	(nc-nc)
Colon / Rectum				
Male	5	10.1	49.7	(16.0-116.0)
Female	9	9.2	97.5	(44.5-185.1)
Esophagus				
Male	4	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	2.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Larynx				
Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	1	2.2	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Lung and Bronchus				
Male	9	12.7	70.9	(32.4-134.6)
Female	9	10.3	87.5	(39.9-166.1)

Male	2	3.6	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	2.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Ovary				
Female	1	2.5	nc	(nc-nc)
Pancreas				
Male	1	1.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Prostate				
Male	22	26.9	81.7	(51.2-123.7)
Stomach				
Male	1	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Testis				
Male	0	1.5	nc	(nc-nc)
Thyroid				
Male	1	0.8	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	4.8	nc	(nc-nc)
All Sites / Types				
Male	67	90.8	73.8	(57.2-93.7)
Female	74	79.4	93.2	(73.2-117.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

158

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	3.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	13	12.8	101.5	(54.0-173.6)	Female	1	1.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Colon / Rectum					Female	0	0.6	nc	(nc-nc)
Male	4	5.6	nc	(nc-nc)	Ovary				
Female	4	4.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.3	nc	(nc-nc)	Male	14	15.2	92.4	(50.4-155.0)
Female	1	0.2	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach					
Male	1	1.5	nc	(nc-nc)		Male	0	0.9	nc	(nc-nc)	
Female	1	0.8	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)	
Larynx						Testis					
Male	1	0.7	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)	
Female	0	0.2	nc	(nc-nc)							
Leukemia						Thyroid					
Male	2	1.1	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)	
Female	0	0.8	nc	(nc-nc)		Female	0	1.0	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	0	0.7	nc	(nc-nc)							
Female	1	0.2	nc	(nc-nc)		Female	4	2.5	nc	(nc-nc)	
Lung and Bronchus						All Sites / Types					
Male	5	7.2	69.7	(22.5-162.7)		Male	39	49.1	79.4	(56.4-108.5)	
Female	1	5.4	nc	(nc-nc)		Female	32	40.1	79.9	(54.6-112.8)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	43	53.8	79.9	(57.8-107.7)	Male	8	28.5	28.0	(12.1-55.3)
Female	23	22.8	101.1	(64.0-151.7)	Female	11	26.4	41.7	(20.8-74.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	12.0	66.5	(28.6-131.0)	Male	6	7.5	80.1	(29.2-174.3)

Breast	Female	11	11.2	98.5	(49.1-176.2)
	Male	1	1.6	nc	(nc-nc)
Cervix Uteri	Female	175	231.4	75.6	(64.8-87.7)
Colon / Rectum	Female	26	11.6	223.4	(145.9-327.3)
	Male	86	83.0	103.7	(82.9-128.0)
Esophagus	Female	79	94.6	83.5	(66.1-104.0)
	Male	13	12.8	101.8	(54.2-174.1)
Hodgkin Lymphoma	Female	8	4.6	173.8	(74.8-342.4)
	Male	6	6.0	100.3	(36.6-218.4)
Kidney & Renal Pelvis	Female	6	5.5	108.4	(39.6-235.9)
	Male	8	21.5	37.3	(16.1-73.5)
Larynx	Female	13	16.1	81.0	(43.1-138.5)
	Male	11	9.4	116.5	(58.1-208.4)
Leukemia	Female	3	2.7	nc	(nc-nc)
	Male	17	18.4	92.5	(53.9-148.2)
Liver and Intrahepatic Bile Ducts	Female	14	17.4	80.5	(44.0-135.1)
	Male	16	10.0	160.6	(91.8-260.9)
Lung and Bronchus	Female	5	4.5	111.3	(35.9-259.6)

Non-Hodgkin Lymphoma	Female	3	7.1	nc	(nc-nc)
	Male	27	28.5	94.8	(62.4-137.9)
Oral Cavity & Pharynx	Female	33	28.9	114.1	(78.6-160.3)
	Male	26	20.4	127.5	(83.3-186.9)
Ovary	Female	8	11.4	69.9	(30.1-137.8)
Pancreas	Female	30	24.2	124.0	(83.6-177.0)
	Male	20	15.4	130.0	(79.4-200.8)
Prostate	Female	13	19.6	66.5	(35.3-113.6)
	Male	173	209.6	82.5	(70.7-95.8)
Stomach	Male	15	14.3	104.8	(58.6-172.9)
	Female	6	10.2	58.5	(21.4-127.4)
Testis	Male	7	11.0	63.6	(25.5-131.0)
Thyroid	Male	4	5.9	nc	(nc-nc)
	Female	12	21.2	56.7	(29.3-99.0)
Uteri Corpus and Uterus, NOS	Female	46	44.5	103.4	(75.7-137.9)
All Sites / Types					

Male	117	103.3	113.3	(93.7-135.7)
Female	82	101.6	80.7	(64.2-100.2)

Male	661	722.6	91.5	(84.6-98.7)
Female	659	776.5	84.9	(78.5-91.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

160
Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	7.6	65.9	(21.2-153.9)	Male	6	3.7	160.8	(58.7-350.0)
Female	2	2.7	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	5	3.7	134.8	(43.4-314.6)
Female	30	27.8	108.0	(72.9-154.2)	Female	4	3.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Colon / Rectum					Female	3	1.4	nc	(nc-nc)
Male	15	11.7	128.7	(72.0-212.4)	Ovary				
Female	22	11.1	198.6	(124.4-300.7)	Female	0	2.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	4	1.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	2	0.6	nc	(nc-nc)	Male	26	31.3	83.2	(54.3-121.9)
Female	1	0.5	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	8	3.0	269.4	(116.0-530.8)	Male	1	2.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Larynx					Testis				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	2.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.4	nc	(nc-nc)					
Female	1	0.5	nc	(nc-nc)	Female	7	5.5	126.5	(50.7-260.7)
Lung and Bronchus					All Sites / Types				
Male	18	15.0	120.3	(71.2-190.1)	Male	108	101.0	107.0	(87.7-129.2)
Female	21	12.7	165.1	(102.2-252.4)	Female	111	91.2	121.7	(100.1-146.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

161
Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	9.9	131.9	(70.2-225.6)	Male	2	5.3	nc	(nc-nc)

Brain and Other Nervous System	Female	5	3.6	138.2	(44.5-322.4)
	Male	1	2.0	nc	(nc-nc)
Breast	Female	3	1.7	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Cervix Uteri	Female	43	39.6	108.5	(78.5-146.2)
Colon / Rectum	Female	4	1.9	nc	(nc-nc)
	Male	13	15.3	85.0	(45.2-145.4)
Esophagus	Female	12	14.6	81.9	(42.3-143.2)
	Male	2	2.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.7	nc	(nc-nc)
	Male	0	0.9	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.8	nc	(nc-nc)
	Male	2	4.0	nc	(nc-nc)
Larynx	Female	1	2.7	nc	(nc-nc)
	Male	4	1.8	nc	(nc-nc)
Leukemia	Female	0	0.5	nc	(nc-nc)
	Male	2	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	3	2.6	nc	(nc-nc)

Multiple Myeloma	Female	2	4.3	nc	(nc-nc)
	Male	1	1.4	nc	(nc-nc)
Non-Hodgkin Lymphoma	Female	1	1.1	nc	(nc-nc)
	Male	3	5.2	nc	(nc-nc)
Oral Cavity & Pharynx	Female	3	4.6	nc	(nc-nc)
	Male	3	3.9	nc	(nc-nc)
Ovary	Female	2	1.9	nc	(nc-nc)
	Female	3	4.0	nc	(nc-nc)
Pancreas	Male	2	2.9	nc	(nc-nc)
	Female	1	3.0	nc	(nc-nc)
Prostate	Male	41	39.7	103.3	(74.1-140.1)
Stomach	Male	4	2.6	nc	(nc-nc)
	Female	1	1.5	nc	(nc-nc)
Testis	Male	5	1.6	303.8	(97.9-709.0)
Thyroid	Male	0	1.0	nc	(nc-nc)
	Female	4	3.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	1	1.9	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	8	7.7	104.0	(44.8-205.0)
Lung and Bronchus					All Sites / Types				
Male	11	19.3	57.1	(28.5-102.2)	Male	119	133.4	89.2	(73.9-106.7)
Female	24	16.9	142.0	(91.0-211.4)	Female	133	127.1	104.7	(87.6-124.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

162
Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	18	7.8	231.3	(137.0-365.5)	Male	4	3.5	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	8	3.6	225.2	(97.0-443.8)
Female	29	29.4	98.7	(66.1-141.8)	Female	6	3.8	156.4	(57.1-340.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
					Female	1	1.5	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	9	11.8	76.1	(34.7-144.5)					
Female	24	14.3	167.6	(107.3-249.3)	Female	1	3.1	nc	(nc-nc)

Esophagus					Pancreas				
Male	2	1.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	0.4	nc	(nc-nc)	Male	34	29.9	113.7	(78.7-158.8)
Female	2	0.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	5	2.8	179.0	(57.7-417.8)	Male	3	2.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Larynx					Testis				
Male	2	1.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
Leukemia					Thyroid				
Male	3	2.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.3	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	6	5.8	104.2	(38.1-226.9)
Lung and Bronchus					All Sites / Types				
Male	14	14.7	95.2	(52.0-159.7)	Male	120	98.1	122.3	(101.4-146.2)
Female	12	14.1	85.1	(43.9-148.7)	Female	100	102.8	97.3	(79.2-118.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	36	40.8	88.2	(61.8-122.1)
Female	14	16.2	86.4	(47.2-145.0)
Brain and Other Nervous System				
Male	5	8.3	60.6	(19.5-141.4)
Female	5	7.3	68.5	(22.1-159.9)
Breast				
Male	1	1.2	nc	(nc-nc)
Female	127	166.4	76.3	(63.6-90.8)
Cervix Uteri				
Female	10	8.0	125.4	(60.0-230.7)
Colon / Rectum				
Male	75	63.1	118.9	(93.6-149.1)
Female	70	66.4	105.4	(82.2-133.2)
Esophagus				
Male	12	9.9	121.2	(62.5-211.7)
Female	1	3.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	3.7	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	18	16.4	109.5	(64.9-173.1)
Female	9	11.5	78.3	(35.7-148.7)
Larynx				
Male	9	7.4	122.3	(55.8-232.1)
Female	4	2.0	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	21.2	47.1	(22.6-86.7)
Female	9	18.0	49.9	(22.8-94.7)
Multiple Myeloma				
Male	2	5.7	nc	(nc-nc)
Female	5	5.1	98.9	(31.9-230.8)
Non-Hodgkin Lymphoma				
Male	26	20.9	124.3	(81.2-182.1)
Female	23	20.3	113.4	(71.8-170.1)
Oral Cavity & Pharynx				
Male	19	15.6	121.4	(73.1-189.7)
Female	8	8.1	98.6	(42.4-194.3)
Ovary				
Female	17	17.1	99.3	(57.8-159.0)
Pancreas				
Male	19	11.7	162.3	(97.7-253.5)
Female	9	13.8	65.3	(29.8-123.9)
Prostate				
Male	140	166.2	84.2	(70.9-99.4)
Stomach				
Male	11	10.7	102.7	(51.2-183.7)
Female	10	7.1	141.7	(67.8-260.6)
Testis				
Male	9	6.8	133.3	(60.8-253.1)
Thyroid				

Male	15	12.9	116.0	(64.9-191.4)
Female	7	11.4	61.3	(24.5-126.2)
Liver and Intrahepatic Bile Ducts				
Male	9	7.6	118.2	(53.9-224.3)
Female	2	3.1	nc	(nc-nc)
Lung and Bronchus				
Male	76	80.3	94.7	(74.6-118.5)
Female	68	74.2	91.6	(71.2-116.2)

Male	1	4.2	nc	(nc-nc)
Female	11	13.9	79.2	(39.5-141.7)
Uteri Corpus and Uterus, NOS				
Female	30	32.5	92.3	(62.3-131.8)
All Sites / Types				
Male	528	550.8	95.9	(87.9-104.4)
Female	468	549.4	85.2	(77.6-93.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

164

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	12	7.6	157.4	(81.2-275.0)
Cervix Uteri				
Female	0	0.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Colon / Rectum						Ovary				
Male	4	3.1	nc	(nc-nc)						
Female	5	2.3	219.5	(70.7-512.3)		Female	1	0.7	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	0.5	nc	(nc-nc)		Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)		Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.2	nc	(nc-nc)		Male	6	8.5	70.8	(25.9-154.1)
Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	0.9	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Larynx						Testis				
Male	0	0.4	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	0.6	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)		Female	1	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	0.4	nc	(nc-nc)						
Female	0	0.1	nc	(nc-nc)		Female	3	1.5	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	4	3.9	nc	(nc-nc)		Male	19	27.3	69.7	(41.9-108.8)
Female	1	2.8	nc	(nc-nc)		Female	30	22.2	134.9	(91.0-192.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	33	42.8	77.0	(53.0-108.2)	Male	23	20.4	112.6	(71.3-168.9)
Female	11	16.4	67.0	(33.4-119.9)	Female	19	16.1	118.2	(71.1-184.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	13	7.4	176.2	(93.7-301.3)	Male	3	5.9	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)	Female	5	5.1	98.1	(31.6-228.9)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.3	nc	(nc-nc)	Male	25	20.3	123.0	(79.6-181.5)
Female	156	163.4	95.5	(81.1-111.7)	Female	19	19.6	97.1	(58.4-151.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	6.8	nc	(nc-nc)	Male	7	15.6	44.8	(17.9-92.3)
Female					Female	6	8.0	75.3	(27.5-163.9)
Colon / Rectum					Ovary				
Male	64	65.6	97.5	(75.1-124.5)	Female	18	16.7	108.0	(64.0-170.6)
Female	40	67.3	59.5	(42.5-81.0)					
Esophagus					Pancreas				
Male	8	10.2	78.1	(33.6-153.9)	Male	6	12.2	49.2	(18.0-107.1)
Female	0	3.3	nc	(nc-nc)	Female	11	14.0	78.3	(39.0-140.1)
Hodgkin Lymphoma					Prostate				
Male	4	2.7	nc	(nc-nc)	Male	174	173.6	100.2	(85.9-116.3)
Female	2	2.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	11	16.4	66.9	(33.3-119.7)	Male	5	11.2	44.8	(14.4-104.6)
Female	7	11.3	61.8	(24.8-127.4)	Female	6	7.2	83.6	(30.5-181.9)
Larynx					Testis				

Male	2	7.5	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)
Leukemia				
Male	15	12.4	120.9	(67.6-199.5)
Female	10	10.8	92.3	(44.2-169.8)
Liver and Intrahepatic Bile Ducts				
Male	7	7.7	91.1	(36.5-187.8)
Female	4	3.2	nc	(nc-nc)
Lung and Bronchus				
Male	51	83.6	61.0	(45.4-80.3)
Female	49	74.3	65.9	(48.8-87.2)

Male	3	3.9	nc	(nc-nc)
Thyroid				
Male	3	3.5	nc	(nc-nc)
Female	16	10.9	147.2	(84.1-239.1)
Uteri Corpus and Uterus, NOS				
Female	43	32.5	132.4	(95.8-178.3)
All Sites / Types				
Male	482	560.5	86.0	(78.5-94.0)
Female	467	537.8	86.8	(79.1-95.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

166
Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	5	2.9	174.4	(56.2-406.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx				
	Male	0	0.1	nc	(nc-nc)		Male	0	0.4	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	1	1.2	nc	(nc-nc)					
	Female	0	0.9	nc	(nc-nc)		Female	0	0.3	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.2	nc	(nc-nc)		Male	1	0.2	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.1	nc	(nc-nc)		Male	1	3.4	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	0.3	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Larynx						Testis				
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	1	0.2	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	1	0.3	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.2	nc	(nc-nc)					
	Female	0	0.0	nc	(nc-nc)		Female	0	0.5	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	0	1.5	nc	(nc-nc)		Male	5	10.9	45.7 (14.7-106.7)
	Female	2	1.0	nc	(nc-nc)		Female	9	8.5	106.4 (48.6-202.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

167
Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	7.8	76.6	(28.0-166.8)	Male	9	4.2	213.0	(97.2-404.5)
Female	0	2.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	29	30.8	94.3	(63.1-135.4)	Female	3	3.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.6	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
					Female	1	1.4	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	11	12.2	90.1	(44.9-161.1)					
Female	12	10.1	118.7	(61.3-207.4)	Female	3	3.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	3	0.7	nc	(nc-nc)	Male	42	33.3	126.3	(91.0-170.7)
Female	1	0.6	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	2	3.3	nc	(nc-nc)	Testis	Male	2	2.1	nc	(nc-nc)
	Female	1	2.0	nc	(nc-nc)		Female	0	1.0	nc	(nc-nc)
	Male	0	1.5	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)						
Leukemia	Male	1	2.5	nc	(nc-nc)	Thyroid	Male	2	0.9	nc	(nc-nc)
	Female	2	1.9	nc	(nc-nc)		Female	6	2.8	216.7	(79.1-471.7)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	1.5	nc	(nc-nc)						
	Female	0	0.5	nc	(nc-nc)		Female	6	6.0	99.8	(36.4-217.2)
Lung and Bronchus						All Sites / Types					
	Male	2	15.7	nc	(nc-nc)		Male	100	108.6	92.1	(74.9-112.0)
	Female	7	12.4	56.3	(22.6-116.0)		Female	84	95.0	88.5	(70.6-109.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

168
Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	7.8	76.6	(28.0-166.6)	Male	4	4.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	9	3.4	261.4	(119.3-496.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	1.6	304.6	(98.2-710.9)	Male	2	1.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)		Male	2	4.1	nc	(nc-nc)
Female	37	32.1	115.4	(81.2-159.0)		Female	3	3.6	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	2	1.6	nc	(nc-nc)		Male	2	3.2	nc	(nc-nc)
						Female	0	1.5	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	12	12.2	98.2	(50.7-171.6)						
Female	9	11.5	78.5	(35.8-148.9)		Female	4	3.2	nc	(nc-nc)
Esophagus						Pancreas				
Male	1	2.0	nc	(nc-nc)		Male	3	2.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)		Female	4	2.4	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.7	nc	(nc-nc)		Male	32	33.0	97.0	(66.4-137.0)
Female	0	0.6	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	6	3.3	181.0	(66.1-394.1)		Male	2	2.1	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)		Female	0	1.2	nc	(nc-nc)
Larynx						Testis				
Male	0	1.5	nc	(nc-nc)		Male	3	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)						
Leukemia						Thyroid				
Male	2	2.5	nc	(nc-nc)		Male	1	0.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)		Female	2	2.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	1.5	nc	(nc-nc)						
Female	0	0.6	nc	(nc-nc)		Female	5	6.2	80.3	(25.9-187.4)
Lung and Bronchus						All Sites / Types				
Male	13	15.5	83.7	(44.5-143.1)		Male	102	108.2	94.3	(76.9-114.4)

Female 11 13.1 83.9 (41.8-150.1)

Female 106 101.2 104.8 (85.8-126.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

169

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	21.1	75.7	(43.2-122.9)	Male	12	10.2	117.9	(60.8-205.9)
Female	11	7.7	142.1	(70.8-254.3)	Female	8	7.8	102.2	(44.0-201.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	3.7	135.7	(43.7-316.6)	Male	1	2.9	nc	(nc-nc)
Female	7	3.2	218.3	(87.4-449.7)	Female	3	2.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)	Male	8	10.1	79.2	(34.1-156.0)
Female	83	79.5	104.4	(83.2-129.5)	Female	15	9.3	160.6	(89.8-264.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	3.3	nc	(nc-nc)	Male	3	7.9	nc	(nc-nc)
					Female	3	3.8	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	22	32.5	67.7	(42.4-102.5)					
Female	29	31.8	91.1	(61.0-130.8)	Female	9	8.1	111.2	(50.7-211.0)
Esophagus					Pancreas				
Male	4	5.1	nc	(nc-nc)	Male	6	6.1	99.0	(36.2-215.5)
Female	0	1.6	nc	(nc-nc)	Female	5	6.6	75.7	(24.4-176.7)
Hodgkin Lymphoma					Prostate				

Male	1	1.3	nc	(nc-nc)	Male	95	86.1	110.3	(89.2-134.8)
Female	0	1.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	7	8.2	85.2	(34.1-175.5)	Male	3	5.5	nc	(nc-nc)
Female	7	5.4	129.5	(51.9-266.9)	Female	2	3.4	nc	(nc-nc)
Larynx					Testis				
Male	1	3.8	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	7	6.2	113.5	(45.5-233.9)	Male	2	1.7	nc	(nc-nc)
Female	5	5.2	96.2	(31.0-224.4)	Female	4	5.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	3.8	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)	Female	21	15.8	132.9	(82.3-203.2)
Lung and Bronchus					All Sites / Types				
Male	18	41.2	43.7	(25.9-69.1)	Male	229	278.0	82.4	(72.1-93.8)
Female	30	35.1	85.4	(57.6-121.9)	Female	269	258.3	104.1	(92.1-117.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

170
Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	93	80.9	114.9	(92.7-140.8)	Male	18	44.6	40.3	(23.9-63.7)
Female	32	34.6	92.6	(63.3-130.7)	Female	20	40.1	49.8	(30.4-77.0)

Brain and Other Nervous System						Multiple Myeloma				
Male	22	18.5	118.7	(74.4-179.7)		Male	14	11.4	122.7	(67.0-205.8)
Female	18	16.5	109.0	(64.6-172.3)		Female	11	10.8	102.0	(50.8-182.5)
Breast						Non-Hodgkin Lymphoma				
Male	1	2.5	nc	(nc-nc)		Male	47	44.1	106.7	(78.4-141.8)
Female	310	354.2	87.5	(78.0-97.8)		Female	48	44.0	109.0	(80.4-144.6)
Cervix Uteri						Oral Cavity & Pharynx				
Female	27	17.7	152.4	(100.4-221.7)		Male	57	32.3	176.7	(133.8-229.0)
Colon / Rectum						Female	21	17.5	120.2	(74.4-183.7)
Male	111	125.8	88.2	(72.6-106.2)		Ovary				
Female	166	141.8	117.0	(99.9-136.3)		Female	31	36.8	84.2	(57.2-119.5)
Esophagus						Pancreas				
Male	28	19.9	140.9	(93.6-203.6)		Male	17	23.4	72.8	(42.4-116.5)
Female	4	6.9	nc	(nc-nc)		Female	35	29.4	118.9	(82.8-165.4)
Hodgkin Lymphoma						Prostate				
Male	6	9.7	61.7	(22.5-134.4)		Male	303	332.3	91.2	(81.2-102.1)
Female	10	8.3	119.9	(57.4-220.5)		Stomach				
Kidney & Renal Pelvis						Male	18	21.5	83.9	(49.7-132.6)
Male	32	33.6	95.4	(65.2-134.6)		Female	12	15.1	79.3	(40.9-138.5)
Female	38	24.7	154.1	(109.0-211.5)		Testis				
Larynx						Male	7	18.4	38.0	(15.2-78.4)
Male	31	14.8	209.0	(142.0-296.6)		Thyroid				
Female	10	4.3	232.2	(111.2-427.0)		Male	2	9.7	nc	(nc-nc)
Leukemia						Female	26	32.2	80.9	(52.8-118.5)
Male	22	27.6	79.8	(50.0-120.8)		Uteri Corpus and Uterus, NOS				
Female	30	25.5	117.8	(79.5-168.2)						
Liver and Intrahepatic Bile Ducts										
Male	18	15.5	116.0	(68.7-183.3)						

Female	12	6.7	177.9	(91.8-310.8)	Female	76	68.9	110.3	(86.9-138.1)
Lung and Bronchus					All Sites / Types				
Male	222	159.4	139.3	(121.6-158.9)	Male	1159	1120.4	103.4	(97.6-109.6)
Female	158	158.0	100.0	(85.0-116.9)	Female	1169	1181.7	98.9	(93.3-104.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

171
Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	23.4	68.5	(39.1-111.2)	Male	6	12.0	50.1	(18.3-108.9)
Female	7	8.7	80.9	(32.4-166.6)	Female	6	9.2	65.4	(23.9-142.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	4.5	111.2	(35.8-259.4)	Male	5	3.3	153.4	(49.4-358.0)
Female	5	3.7	135.3	(43.6-315.7)	Female	4	2.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.7	nc	(nc-nc)	Male	17	11.8	143.7	(83.7-230.1)
Female	86	88.6	97.1	(77.7-119.9)	Female	14	10.8	130.2	(71.1-218.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	4.0	nc	(nc-nc)	Male	6	8.9	67.3	(24.6-146.6)
Colon / Rectum					Female	4	4.3	nc	(nc-nc)
Male	37	36.0	102.7	(72.3-141.6)	Ovary				
Female	27	35.1	76.9	(50.7-111.9)	Female	7	9.0	77.5	(31.1-159.7)
Esophagus					Pancreas				

	Male	5	5.7	88.2	(28.4-205.9)
	Female	0	1.7	nc	(nc-nc)
Hodgkin Lymphoma					
	Male	5	2.0	246.1	(79.3-574.2)
	Female	0	1.5	nc	(nc-nc)
Kidney & Renal Pelvis					
	Male	11	9.3	117.8	(58.7-210.7)
	Female	2	6.2	nc	(nc-nc)
Larynx					
	Male	6	4.2	142.2	(51.9-309.4)
	Female	0	1.1	nc	(nc-nc)
Leukemia					
	Male	10	7.2	139.8	(66.9-257.1)
	Female	5	5.8	86.0	(27.7-200.8)
Liver and Intrahepatic Bile Ducts					
	Male	2	4.3	nc	(nc-nc)
	Female	1	1.6	nc	(nc-nc)
Lung and Bronchus					
	Male	47	46.1	102.0	(74.9-135.6)
	Female	29	40.6	71.4	(47.8-102.5)

	Male	5	6.7	74.7	(24.1-174.2)
	Female	5	7.3	68.4	(22.1-159.7)
Prostate					
	Male	99	95.7	103.5	(84.1-126.0)
Stomach					
	Male	5	6.1	82.2	(26.5-191.8)
	Female	2	3.6	nc	(nc-nc)
Testis					
	Male	4	3.5	nc	(nc-nc)
Thyroid					
	Male	4	2.3	nc	(nc-nc)
	Female	6	6.7	88.9	(32.5-193.5)
Uteri Corpus and Uterus, NOS					
	Female	26	17.5	148.8	(97.2-218.1)
All Sites / Types					
	Male	308	314.1	98.1	(87.4-109.6)
	Female	263	290.8	90.4	(79.8-102.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	12	9.9	121.0	(62.4-211.3)		Male	2	5.3	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)		Female	2	4.1	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	2	2.0	nc	(nc-nc)		Male	0	1.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)		Female	1	1.0	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)		Male	3	5.2	nc	(nc-nc)
Female	47	38.9	120.8	(88.8-160.7)		Female	6	4.3	140.5	(51.3-305.7)
Cervix Uteri						Oral Cavity & Pharynx				
Female	3	1.9	nc	(nc-nc)		Male	2	4.1	nc	(nc-nc)
Colon / Rectum						Female	0	1.8	nc	(nc-nc)
Male	15	15.5	97.0	(54.2-160.0)		Ovary				
Female	19	13.3	143.2	(86.2-223.7)		Female	2	3.9	nc	(nc-nc)
Esophagus						Pancreas				
Male	4	2.5	nc	(nc-nc)		Male	1	2.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)		Female	2	2.7	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.9	nc	(nc-nc)		Male	40	41.6	96.1	(68.7-130.9)
Female	1	0.7	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	4	2.6	nc	(nc-nc)
Male	7	4.2	167.2	(67.0-344.4)		Female	0	1.4	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)		Testis				
Larynx						Male	0	1.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)		Thyroid				
Female	0	0.5	nc	(nc-nc)		Male	0	1.0	nc	(nc-nc)
Leukemia										
Male	4	3.1	nc	(nc-nc)						

Female	3	2.4	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	2.0	255.0	(82.2-595.0)					
Female	1	0.6	nc	(nc-nc)	Female	3	7.6	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	21	19.8	106.3	(65.8-162.5)	Male	130	136.4	95.3	(79.6-113.2)
Female	16	15.9	100.8	(57.6-163.7)	Female	121	120.4	100.5	(83.4-120.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

173
Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	86	82.4	104.3	(83.4-128.8)	Male	38	42.4	89.7	(63.4-123.1)
Female	35	33.6	104.3	(72.6-145.0)	Female	27	36.7	73.5	(48.4-106.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	18	16.7	107.7	(63.8-170.2)	Male	13	11.5	113.3	(60.3-193.8)
Female	13	15.1	85.9	(45.7-146.8)	Female	18	10.4	172.3	(102.0-272.3)
Breast					Non-Hodgkin Lymphoma				
Male	3	2.5	nc	(nc-nc)	Male	44	42.1	104.4	(75.9-140.2)
Female	299	338.5	88.3	(78.6-98.9)	Female	44	41.8	105.3	(76.5-141.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	18	16.1	111.9	(66.3-176.9)	Male	37	30.9	119.6	(84.2-164.9)
					Female	21	16.6	126.2	(78.1-192.9)
Colon / Rectum					Ovary				

Male	152	127.0	119.7	(101.5-140.4)
Female	128	138.1	92.7	(77.3-110.2)
Esophagus				
Male	21	19.7	106.8	(66.1-163.3)
Female	6	6.7	89.0	(32.5-193.7)
Hodgkin Lymphoma				
Male	9	7.7	116.8	(53.3-221.8)
Female	9	6.9	131.2	(59.9-249.1)
Kidney & Renal Pelvis				
Male	31	32.5	95.3	(64.7-135.2)
Female	28	23.6	118.7	(78.8-171.5)
Larynx				
Male	27	14.5	185.9	(122.4-270.4)
Female	11	4.1	266.2	(132.7-476.4)
Leukemia				
Male	33	26.3	125.3	(86.2-176.0)
Female	27	23.9	112.9	(74.4-164.3)
Liver and Intrahepatic Bile Ducts				
Male	29	15.1	191.7	(128.4-275.3)
Female	9	6.5	138.0	(63.0-262.0)
Lung and Bronchus				
Male	195	159.8	122.0	(105.5-140.4)
Female	196	152.4	128.6	(111.2-147.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

174
Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	18	16.5	108.8	(64.4-171.9)	Male	10	8.0	125.5	(60.1-230.9)
Female	7	5.4	129.5	(51.9-266.9)	Female	14	5.7	245.9	(134.3-412.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	7	7.9	88.5	(35.4-182.3)
Female	60	57.4	104.6	(79.8-134.7)	Female	9	6.6	135.4	(61.8-257.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	2.5	nc	(nc-nc)	Male	5	6.1	81.4	(26.2-190.0)
Colon / Rectum					Female	4	2.7	nc	(nc-nc)
Male	35	25.4	137.7	(95.9-191.5)	Ovary				
Female	23	21.7	106.0	(67.1-159.0)	Female	2	5.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	5	4.0	124.8	(40.2-291.3)	Male	3	4.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	1.1	nc	(nc-nc)	Male	86	68.1	126.3	(101.1-156.0)
Female	1	0.9	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	6	4.3	139.0	(50.8-302.6)
Male	5	6.5	77.5	(25.0-180.9)	Female	0	2.2	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	Testis				
Larynx					Male	2	1.6	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)					

Female	0	0.7	nc	(nc-nc)
Leukemia				
Male	4	4.8	nc	(nc-nc)
Female	5	3.6	139.0	(44.8-324.4)
Liver and Intrahepatic Bile Ducts				
Male	1	3.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Lung and Bronchus				
Male	27	32.5	83.0	(54.7-120.8)
Female	18	25.6	70.3	(41.7-111.2)

Thyroid

Male	1	1.4	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	9	11.6	77.9	(35.5-147.8)
--------	---	------	------	--------------

All Sites / Types

Male	236	218.5	108.0	(94.6-122.7)
Female	183	184.0	99.5	(85.6-115.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;